Investigation of epistasis between DAOA and 5HTR1A variants on clinical outcomes in patients with schizophrenia.

PURPOSE In two recent studies of our group, rs10042486, a single-nucleotide polymorphism (SNP) within 5HTR1A, and rs7139958, a SNP within the d-amino acid oxidase activator (DAOA) were found to be associated with clinical improvement, as detected by the positive symptom subscale of the Positive and Negative Symptoms Scale (PANSS) in a sample 221 Korean schizophrenia patients treated with various antipsychotics. METHODS The existence of possible epistatic interactions between rs10042486 and rs7139958 influencing PANSS-positive subscale improvement scores in the same sample was investigated. RESULTS No significant epistatic interaction was observed. Furthermore, the independent associations observed between rs10042486, rs7139958, and PANSS-positive subscale improvement scores in earlier studies were no longer significant when they were included in our model. CONCLUSION Although limited by some methodological shortcomings, our results preliminarily point to the possibility that positive genetic associations observed in some samples could not be replicated in different samples because of the existence of consistent differences in the genotype frequencies of other genetic polymorphisms that epistatically interact with the specific variants under investigation in a given study.

[1]  T. Wassink,et al.  Statistical Epistasis and Progressive Brain Change in Schizophrenia: An Approach for Examining the Relationships Between Multiple Genes , 2011, Molecular Psychiatry.

[2]  A. Serretti,et al.  Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics , 2012, European Archives of Psychiatry and Clinical Neuroscience.

[3]  M. Arranz,et al.  Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia , 2011, CNS drugs.

[4]  M. Gill,et al.  Epistasis between neurochemical gene polymorphisms and risk for ADHD , 2011, European Journal of Human Genetics.

[5]  N. Risch,et al.  Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. , 2009, JAMA.

[6]  John M. Davis,et al.  Defining ‘Response’ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs , 2007, Neuropsychopharmacology.

[7]  Elliot S. Gershon,et al.  Allelic association of G72/G30 with schizophrenia and bipolar disorder: A comprehensive meta-analysis , 2008, Schizophrenia Research.

[8]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[9]  P. Phillips Epistasis — the essential role of gene interactions in the structure and evolution of genetic systems , 2008, Nature Reviews Genetics.

[10]  Chris S. Haley,et al.  Epistasis: too often neglected in complex trait studies? , 2004, Nature Reviews Genetics.

[11]  P. McGuffin,et al.  Genetic basis of schizophrenia , 1995, The Lancet.

[12]  Marquis P. Vawter,et al.  Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population , 2011, Schizophrenia Research.

[13]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[14]  A. Serretti,et al.  DAOA variants and schizophrenia: Influence on diagnosis and treatment outcomes , 2011, International journal of psychiatry in clinical practice.

[15]  M. Posternak,et al.  Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? , 2002, The American journal of psychiatry.

[16]  A. Malhotra,et al.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction , 2011, Expert opinion on drug metabolism & toxicology.

[17]  Sven Cichon,et al.  The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries? , 2005, Schizophrenia bulletin.

[18]  The challenge of uncovering the genetics of anxiety , 2012, Acta psychiatrica Scandinavica.